Latest From Sue Darcey
Coverage Decisions For AlloMap Molecular Testing To Detect Cardiac Allograft Rejections Left Up To MACs
The US CMS has proposed that due to low Medicare use, it will not nationally cover AlloMap molecular tests to detect cardiac allograft rejections.
The US watchdog agency accedes to three senators’ request to look into political pressures placed on the FDA and the CDC to alter the science behind their COVID-19 responses.
The US Medicare agency coupled its proposed coverage memo on colorectal cancer screens based on blood-based biomarker tests with a note that the Epi proColon assay does not meet its criteria.
During her confirmation hearings, Judge Amy Coney Barrett denied it’s her goal to end all Affordable Care Act coverage, but some senators and legal experts disagree. And if the ACA is struck down, coverage for chronic disease treated with medical devices – including cancer, heart disease and diabetes – could fall by the wayside.
US senatorial friends of the device industry running competitive races in 2020 are being aided by medtech PAC dollars this fall.
The US Medicare agency will allow reimbursements for a bevy of new telemedicine services during the COVID-19 public health emergency, it announced on 14 October.